血管抑制蛋白2在三阴性乳腺癌中的功能及其调控可变剪接机制

doi:10.3969/j.issn.1674-8115.2024.12.005

摘要/Abstract

摘要：

目的·探索血管抑制蛋白2（vasohibin-2，VASH2）在三阴性乳腺癌（triple-negative breast cancer，TNBC）中的表达及VASH2通过调控基因表达和可变剪接在TNBC发生发展中的作用机制。方法·通过基因型-组织表达数据库（Genotype-Tissue Expression，GTEx）联合癌症基因组图谱数据库（The Cancer Genome Atlas，TCGA）比较VASH2在TNBC中与正常乳腺组织中的表达差异，并分析VASH2在TNBC中的甲基化水平。在TNBC细胞系MDA-MB-231中对VASH2过表达，并进行转录组测序，分析受VASH2所调控的差异表达基因及可变剪接基因。结果·VASH2在TNBC组织中与正常组织及其他乳腺癌分型比较表达水平显著提高。VASH2基因的低甲基化可能是VASH2在TNBC 中表达上调的原因之一。VASH2过表达后引起81个基因显著差异表达，其中上调的基因23个，下调的基因58个。VASH2过表达后可变剪接水平发生显著变化的基因主要富集在细胞周期、p53信号通路上。结论·VASH2可能通过调控TNBC中基因可变剪接促进其发生和发展。

关键词: 血管抑制蛋白2, 三阴性乳腺癌, 可变剪接, p53信号通路, 细胞周期

Abstract:

Objective ·To explore the role of vasohibin-2 (VASH2) in the regulation of proliferation and metastasis of triple-negative breast cancer (TNBC) cells, and explore the mechanism of VASH2 in the occurrence and development of TNBC through regulation of gene expression and alternative splicing. Methods ·TCGA-GTEx was used to analyze the expression of VASH2 in TNBC. VASH2 methylation levels in TNBC were also analyzed. VASH2 was overexpressed in the MDA-MB-231 human TNBC cell line and transcriptome sequencing was performed. Differentially expressed genes and alternatively spliced genes regulated by VASH2 were analyzed to explore the mechanism of action of VASH2 in TNBC. Results ·VASH2 was significantly overexpressed in TNBC compared to the normal tissues. Hypomethylation of the VASH2 gene was implicated in the upregulation of VASH2 expression in TNBC. Overexpression of VASH2 caused significant differential expression of 81 genes, of which 23 genes were up-regulated and 58 genes were down-regulated. Genes with significantly altered alternative splicing levels due to VASH2 overexpressed were enriched in cell cycle and p53 signaling pathways. Conclusion ·VASH2 regulates the alternative splicing of TNBC oncogenes and promotes TNBC occurrence and development.

Key words: vasohibin-2 (VASH2), triple-negative breast cancer (TNBC), alternative splicing, p53 signaling pathway, cell cycle

中图分类号:

R737.9

王卫, 王红丽, 阿力比亚提·艾尼, 衣力亚尔·肉苏, 阿依努尔, 杨亮. 血管抑制蛋白2在三阴性乳腺癌中的功能及其调控可变剪接机制[J]. 上海交通大学学报（医学版）, 2024, 44(12): 1526-1535.

WANG Wei, WANG Hongli, ALIBIYATI·i Ain, YILIYAER· Rousu, AYI NUER, YANG Liang. Function of vasohibin-2 and the mechanism of alternative splicing in triple-negative breast cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(12): 1526-1535.

图/表 6

图1 VASH2 的差异表达Note： A. Differential expression between TNBC and normal breast tissues. B. Differential expression between TNBC and paired cancer-adjacent tissues. C. Comparative analysis between TNBC and nonTNBC. ①P<0.001, ②P=0.035.

Fig 1 Differential expression of VASH2

图2 VASH2 在TNBC中的甲基化分析Note： A. Methylation site correlation analysis in the VASH2 promoter. B. Methylation levels corresponded to VASH2 expression. C. Correlation analysis between the degree of methylation sites and the expression of VASH2. ①P<0.001, ②P=0.011, ③P=0.029, ④P=0.004, ⑤P=0.002.

Fig 2 Methylated analysis of VASH2 in TNBC

图3 验证VASH2在MDA-MB-231细胞中高表达Note： A. RT-qPCR results of OE-VASH2 and the control groups. B. Western blotting results. ①P<0.001, compared with the control groups.

Fig 3 Verification of high expression of VASH2 in MDA-MB-231 cells

图4 VASH2 调控转录组的RNA-seq分析Note： A. Volcano map based on differentially expressed genes (DEGs). B. Heat map of expression levels of DEGs. C. GO function enrichment bar chart. D/E. Bar charts showing KEGG pathway enrichment of downregulated DEGs (D) and upregulated DEGs (E).

Fig 4 RNA-seq analysis of VASH2-regulated transcriptome

图5 MDA-MB-231细胞中 VASH2 调控的可变剪接事件及功能分析Note： A. Classification of RASEs. B?D. Regulation of top 10 enriched GO biological processes for VASH2. E. Top 10 enriched KEGG pathways for VASH2.

Fig 5 RASEs in MDA-MB-231 cells and function analysis

图6 富含细胞凋亡事件的可变剪接基因Note： A. Wayne diagram of the gene set with significantly altered AS expression levels in the cell cycle and p53 signaling pathway. B. ASE of the VASH2-regulated gene TSC2 and IGV-sashimi plot showing A3SS & ES events. C.ASE of the VASH2-regulated gene SMAD2 and IGV-sashimi plot showing ES events. D. ASE of the VASH2-regulated gene CASP8. ①P=0.006, ②P=0.017, ③P=0.027.

Fig 6 Apoptosis-enriched alternative splicing genes

参考文献 34

1	DERAKHSHAN F, REIS-FILHO J S. Pathogenesis of triple-negative breast cancer[J]. Annu Rev Pathol, 2022, 17: 181-204.
2	ZONG Y, PEGRAM M. Research advances and new challenges in overcoming triple-negative breast cancer[J]. Cancer Drug Resist, 2021, 4(3): 517-542.
3	MERIKHIAN P, EISAVAND M R, FARAHMAND L. Triple-negative breast cancer: understanding Wnt signaling in drug resistance[J]. Cancer Cell Int, 2021, 21(1): 419.
4	BURSTEIN H J, CURIGLIANO G, THÜRLIMANN B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol. 2021,32(10):1216-1235.
5	TU J J, FANG Y L, HAN D F, et al. Activation of nuclear factor-κB in the angiogenesis of glioma: insights into the associated molecular mechanisms and targeted therapies[J]. Cell Prolif, 2021, 54(2): e12929.
6	TAN X B, LIAO Z F, ZOU S Y, et al. VASH2 promotes cell proliferation and resistance to doxorubicin in non-small cell lung cancer via AKT signaling[J]. Oncol Res, 2020, 28(1): 3-11.
7	NINOMIYA Y, OZAWA S, OGUMA J, et al. Expression of vasohibin-1 and-2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus[J]. Oncol Lett, 2018, 16(4): 5265-5274.
8	SATO Y. The vasohibin family: a novel family for angiogenesis regulation[J]. J Biochem, 2013, 153(1): 5-11.
9	YAMAMOTO M, OZAWA S, NINOMIYA Y, et al. Plasma vasohibin-1 and vasohibin-2 are useful biomarkers in patients with esophageal squamous cell carcinoma[J]. Esophagus, 2020, 17(3): 289-297.
10	KITAHARA S, SUZUKI Y, MORISHIMA M, et al. Vasohibin-2 modulates tumor onset in the gastrointestinal tract by normalizing tumor angiogenesis[J]. Mol Cancer, 2014, 13: 99.
11	NORITA R, SUZUKI Y, FURUTANI Y, et al. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling[J]. Cancer Sci, 2017, 108(3): 419-426.
12	TU M, LI Z J, LIU X, et al. Vasohibin 2 promotes epithelial-mesenchymal transition in human breast cancer via activation of transforming growth factor β 1 and hypoxia dependent repression of GATA-binding factor 3[J]. Cancer Lett, 2017, 388: 187-197.
13	MA H R, CAO L, WANG F, et al. Filamin B extensively regulates transcription and alternative splicing, and is associated with apoptosis in HeLa cells[J]. Oncol Rep, 2020, 43(5): 1536-1546.
14	YISA S B, FEI W M, YAXUN W M, et al. ATP5A1 participates in transcriptional and posttranscriptional regulation of cancer-associated genes by modulating their expression and alternative splicing profiles in HeLa cells[J]. Technol Cancer Res Treat, 2021, 20: 15330338211039126.
15	沈鑫鑫, 金磊, 赵倩, 等. 血管抑制蛋白2在乳腺癌中的表达情况及其对患者预后的影响[J]. 安徽医学, 2021, 42(2): 144-148.
	SHEN X X, JIN L, ZHAO Q, et al. Expression of vasohibin-2 and its effect on prognosis of breast cancer[J]. Anhui Medical Journal, 2021, 42(2): 144-148.
16	GAO Y, ZHANG W Z, LIU C W, et al. MiR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB[J]. Sci Rep, 2019, 9(1): 18844.
17	ZENG X, QU X J, ZHAO C Y, et al. FEN1 mediates miR-200a methylation and promotes breast cancer cell growth via MET and EGFR signaling[J]. FASEB J, 2019, 33(10): 10717-10730.
18	ANSARI J, SHACKELFORD R E, EL-OSTA H. Epigenetics in non-small cell lung cancer: from basics to therapeutics[J]. Transl Lung Cancer Res, 2016, 5(2): 155-171.
19	LI R, YANG Y E, YIN Y H, et al. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers[J]. J Transl Med, 2019, 17(1): 324.
20	CHEN Y C, LIU X R, LI Y K, et al. Lung cancer therapy targeting histone methylation: opportunities and challenges[J]. Comput Struct Biotechnol J, 2018, 16: 211-223.
21	WANG B, YANG L, ZHAO Q, et al. Vasohibin 2 as a potential predictor of aggressive behavior of triple-negative breast cancer[J]. Am J Transl Res, 2017, 9(6): 2911-2919.
22	LI F X, HU Y J, QI S T, et al. Structural basis of tubulin detyrosination by vasohibins[J]. Nat Struct Mol Biol, 2019, 26(7): 583-591.
23	VAN DER LAAN S, LÉVÊQUE M F, MARCELLIN G, et al. Evolutionary divergence of enzymatic mechanisms for tubulin detyrosination[J]. Cell Rep, 2019, 29(12): 4159-4171.e6.
24	NIEUWENHUIS J, ADAMOPOULOS A, BLEIJERVELD O B, et al. Vasohibins encode tubulin detyrosinating activity[J]. Science, 2017, 358(6369): 1453-1456.
25	JOERGER A C, FERSHT A R. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches[J]. Annu Rev Biochem, 2016, 85: 375-404.
26	ZHANG H, ZHANG X, LI X, et al. Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer[J]. J Cell Physiol, 2018, 234(1): 619-631.
27	MISSAOUI N, LANDOLSI H, MESTIRI S, et al. Immunohistochemical analysis of c-erbB-2, Bcl-2, p53, p21^(WAF1/Cip1), p63 and Ki-67 expression in hydatidiformmoles[J]. Pathol Res Pract,2019,215(3):446-452.
28	LO W, PARKHURST M, ROBBINS P F, et al. Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer[J]. Cancer Immunol Res,2019,7(4):534-543.
29	SCHAEFER I M, HORNICK J L, SHOLL L M, et al. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour[J]. Histopathology, 2017, 70(7): 1138-1146.
30	DONNELLAN R, CHETTY R. Cyclin E in human cancers[J]. FASEB J, 1999, 13(8): 773-780.
31	KEYOMARSI K, O'LEARY N, MOLNAR G, et al. Cyclin E, a potential prognostic marker for breast cancer[J]. Cancer Res, 1994, 54(2): 380-385.
32	HUANG X, SHAO D, WU H W, et al. Genomic profiling comparison of germline BRCA and non-BRCA carriers reveals CCNE1 amplification as a risk factor for non-BRCA carriers in patients with triple-negative breast cancer[J]. Front Oncol, 2020, 10: 583314.
33	杨睿, 陈俊霞. 环状RNA hsa_circ_0058514在三阴性乳腺癌中的表达及作用研究[J]. 中国癌症杂志, 2019, 29(1): 9-18.
	YANG R, CHEN J X. Effects of circular RNA hsa_circ_0058514 on the development and progression of triple-negative breast cancer[J]. China Oncology, 2019, 29(1): 9-18.
34	LIU Z, FU Q S, WANG Y, et al. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways[J]. Biomed Pharmacother, 2021, 134: 111144.

[1]	韩依杉, 徐梓淇, 陶梦玉, 范广建, 余波. PRMT6促进乳腺癌细胞的增殖和迁移[J]. 上海交通大学学报（医学版）, 2024, 44(8): 999-1010.
[2]	薛煜, 张海龙, 雷鸣. 癌-睾丸抗原SPANXB在肝癌中的表达及其影响肝癌进展的机制研究[J]. 上海交通大学学报（医学版）, 2024, 44(7): 801-813.
[3]	施泽纶, 王青, 何雯, 傅唯佳, 王颖雯, 韩晓, 张晓波. 纳米塑料诱导肺泡Ⅱ型上皮细胞DNA损伤加重重症哮喘[J]. 上海交通大学学报（医学版）, 2024, 44(11): 1391-1405.
[4]	王晓玲, 葛梦凯, 沈少明. PTEN对FoxM1可变剪接的调控及该过程在肿瘤细胞迁移中的作用[J]. 上海交通大学学报（医学版）, 2023, 43(11): 1339-1347.
[5]	王斓茜, 马官荣, 姜咏竹, 常秀林, 方廖琼, 白晋. 大肠埃希菌外膜囊泡对乳腺癌细胞增殖及荷瘤小鼠肿瘤生长的影响[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1245-1254.
[6]	宗春燕, 何杰, 张哲, 贾仁兵, 沈键锋. APOBEC3B调控葡萄膜黑色素瘤复制应激的研究[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1034-1044.
[7]	徐斐翔, 汪升, 薛明明, 童朝阳, 陈玉梅. 长链非编码RNA-B230352I09表达改变对H9C2心肌细胞增殖及周期的影响[J]. 上海交通大学学报（医学版）, 2022, 42(5): 578-582.
[8]	朱楠, 刘炳亚, 俞焙秦. 肌盲样蛋白1在恶性肿瘤中作用的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(10): 1474-1481.
[9]	陈翠, 金叶, 王琳, 李红丽, 万财凤, 姜立新. 30例乳腺化生性癌的多种影像学对比分析[J]. 上海交通大学学报(医学版), 2022, 42(1): 70-76.
[10]	季艳杰, 罗浩, 蔡海燕, 刘欣宇, 金诗佳, 粟深月, 徐含章, 雷虎, 吴英理. CDDO-Me对三阴性乳腺癌细胞泛素特异性蛋白酶2a活性及细胞增殖的抑制作用[J]. 上海交通大学学报(医学版), 2021, 41(8): 1025-1032.
[11]	赫玮, 左勇. 冬凌草甲素上调PLK1对Jurkat细胞细胞周期的影响[J]. 上海交通大学学报(医学版), 2021, 41(5): 603-611.
[12]	顾琦晟, 张米粒, 曹灿, 李继坤. 基于TCGA数据库分析胃癌可变剪接与肿瘤免疫的关系[J]. 上海交通大学学报(医学版), 2021, 41(4): 448-458.
[13]	张凤春1, 2，张硕渊3，陈天恩3，徐迎春3. PD-1/PD-L1通路在三阴性乳腺癌预后预测及治疗中的意义[J]. 上海交通大学学报（医学版）, 2020, 40(1): 128-.
[14]	王佳琳，季迪，陈祥，杨博，余林. miR-218-2-3P靶向SIN3A基因影响NK/T细胞淋巴瘤的增殖和凋亡[J]. 上海交通大学学报（医学版）, 2019, 39(12): 1394-.
[15]	狄芳芳，刘建胜，李尚，杜艳芝. 转录因子 C/EBPβ在子宫蜕膜化中的作用及机制研究进展[J]. 上海交通大学学报（医学版）, 2017, 37(6): 865-.